Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 2 Study of AB122 and AB154 in Front Line Non-Small Cell Lung Cancer Patients

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Disease Types: Lung

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

For more information:

https://clinicaltrials.gov/ct2/show/NCT04262856?term=A+Phase+2+Study+to+Evaluate+the+Safety+and+Efficacy+of+AB122+Monotherapy%2C+AB154+in+Combination+with+AB122%2C+and+AB154+in+Combination+with+AB122+and+AB928+in+Front-Line%2C+Non-Small+Cell+Lung+Cancer&draw=2&rank=1